Literature DB >> 22966385

Genetic diagnosis of patients with esophageal cancer using FISH.

Idiris Awut1, Madiniyet Niyaz, Xie Huizhong, Hadeti Biekemitoufu, Zhang Hong Yan, Zhang Zhu, Ilyar Sheyhedin, Zhang Changmin, Zhangli Wei, Wen Hao.   

Abstract

This study aimed to the clarify the diagnostic efficacy of fluorescence in situ hybridization (FISH) in Kazakh patients with esophageal cancer (EC). FISH was compared with the pathological examination of biopsy specimens with DNA probes. We enrolled 20 patients, of which 15 were males and 5 females, with an average age of 58.3 years, who had abnormal esophaguses on barium radiological digital imaging. Touch preparations were performed on biopsy specimens from all of the patients and were examined using FISH for chromosomal abnormalities. We compared the FISH results with the pathology slides stained with hematoxylin and eosin. Classification, according to pathology, identified 2 cases of class II, 3 cases of IIIa, 1 case of IIIb, 2 cases of IV, 12 cases of class V and no cases of class I. The cases classified as class IIIb or higher were considered to be positive for cancer. Using histopathology, 10 cases were diagnosed with squamous cell carcinoma and 5 were diagnosed as adenocarcinoma, with one case being false-negative. Thus, the sensitivity of the pathological examination was 93% and the specificity was 100%. Using FISH, 16 cases showed aberrant copy numbers in either chromosome 3 or 17. By comparison, pathology did not reveal any false-positive or false-negative cases with a sensitivity and specificity of 100%. The centromeres of chromosome 3 copy numbers was significantly higher (p=0.035) than the centromeres of chromosome 17. Our study compared FISH to diagnose aneusomic esophageal cancer cells with the pathology of biopsied tissue. Our findings suggest that FISH is a useful and objective assay for the detection of malignant cells of esophageal cancer. In our study, the centromeres of chromosome 3 was the more sensitive probe for the diagnosis of esophageal cancer in Kazakh patients.

Entities:  

Year:  2010        PMID: 22966385      PMCID: PMC3436409          DOI: 10.3892/ol_00000142

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

Review 1.  Barrett esophagus: histology and pathology for the clinician.

Authors:  Robert D Odze
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

2.  Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden.

Authors:  Shahram Bahmanyar; Weimin Ye
Journal:  Nutr Cancer       Date:  2006       Impact factor: 2.900

3.  Genomic instability in precancerous lesions before inactivation of tumor suppressors p53 and APC in patients.

Authors:  Youxin Yang; Johannes Fruehauf; Shuanglin Xiang; Chiang J Li
Journal:  Cell Cycle       Date:  2006-07-01       Impact factor: 4.534

4.  Quantitative detection of lung cancer cells by fluorescence in situ hybridization: comparison with conventional cytology.

Authors:  Haruhiko Nakamura; Idiris Aute; Norihito Kawasaki; Masahiko Taguchi; Tatsuo Ohira; Harubumi Kato
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

5.  A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.

Authors:  Emily G Barr Fritcher; Shannon M Brankley; Benjamin R Kipp; Jesse S Voss; Michael B Campion; Larry E Morrison; Mona S Legator; Lori S Lutzke; Kenneth K Wang; Thomas J Sebo; Kevin C Halling
Journal:  Hum Pathol       Date:  2008-07-07       Impact factor: 3.466

Review 6.  Chromosome aberrations in solid tumors.

Authors:  Donna G Albertson; Colin Collins; Frank McCormick; Joe W Gray
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

Review 7.  Fluorescence in situ hybridization in diagnostic cytology.

Authors:  Kevin C Halling; Benjamin R Kipp
Journal:  Hum Pathol       Date:  2007-08       Impact factor: 3.466

Review 8.  Aneuploidy and cancer.

Authors:  Harith Rajagopalan; Christoph Lengauer
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

9.  Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.

Authors:  Y Kawaguchi; K Kono; K Mimura; F Mitsui; H Sugai; H Akaike; H Fujii
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

10.  Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma.

Authors:  S H Doak; G J S Jenkins; E M Parry; A P Griffiths; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more
  2 in total

1.  Molecular pathological diagnosis for early esophageal cancer in Kazakh patients.

Authors:  Idiris Awut; Madiniyet Niyaz; Hadeti Biekemitoufu; Zhu Zhang; Ilyar Sheyhedin; Wen Hao
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

2.  CEP3 and CEP17 DNA probe potential in the genetic diagnosis and prognostic prediction of esophageal squamous cell cancer.

Authors:  Madiniyat Niyaz; Ablajan Abdurahman; Abdugheni Turghun; Idiris Awut
Journal:  Exp Ther Med       Date:  2016-02-16       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.